UVM Health Drops GLP-1 Coverage: What to Do

If you're a UVM Health employee taking a GLP-1 medication for weight loss, you may soon be paying out of pocket for a drug that costs over $1,000 per month. Understanding your options now, before coverage ends, could save you thousands of dollars and protect your health progress.

What UVM Health Is Doing and Why It Matters

UVM Health Network, one of Vermont's largest healthcare employers, is eliminating coverage for GLP-1 medications used for weight loss from its employee benefits plan. The decision affects workers who rely on drugs like semaglutide (Wegovy) or tirzepatide (Mounjaro) to manage their weight.

This is not an isolated move. Employers across the country have been quietly pulling back on GLP-1 obesity coverage over the past two years as drug costs strained benefit budgets. What makes the UVM Health situation notable is that this is a healthcare organization, the very type of employer you might expect to prioritize employee access to evidence-based obesity treatment.

The decision signals just how expensive these medications have become for plan sponsors, even those deeply invested in employee health outcomes.

Why Employers Are Pulling Back

GLP-1 medications are among the most expensive drug classes in the country. A single month of Wegovy (semaglutide 2.4 mg) carries a list price above $1,300. When multiplied across hundreds or thousands of employees, the annual cost to an employer can run into the millions.

Many employers added GLP-1 coverage during a wave of enthusiasm for these drugs in 2022 and 2023. Now, facing actual claims data, some are reconsidering. The result: employees who started treatment under employer coverage are suddenly left without a financial safety net.

The Real Cost of GLP-1 Medications Without Insurance

Losing employer coverage does not mean losing access, but it does mean confronting the true sticker price of these drugs. Here is a realistic look at what you might pay without insurance:

These are approximate list prices and vary by pharmacy and location. Your actual out-of-pocket cost depends on your specific plan details and what coverage, if any, remains through your spouse or a marketplace plan.

Immediate Steps to Take If You Lose Coverage

If your GLP-1 coverage is being cut, acting quickly is important. Stopping a GLP-1 medication abruptly can lead to weight regain and metabolic setbacks, so you want a plan in place before your last covered fill.

1. Confirm Your Last Covered Fill Date

Contact your HR department or benefits administrator to get the exact date your coverage ends. Then call your pharmacy to understand when you need to fill your next prescription to still capture that benefit.

2. Talk to Your Prescribing Doctor

Your doctor needs to know about this change. They can discuss whether adjusting your dose (to a lower, potentially cheaper tier) makes sense, or whether there are medically documented reasons that could support an insurance appeal.

3. Check Manufacturer Savings Programs

Novo Nordisk (maker of Wegovy and Ozempic) and Eli Lilly (maker of Mounjaro and Zepbound) both offer savings cards and patient assistance programs for eligible patients. These programs are typically income-based and may not be available to everyone, but they are worth investigating immediately.

• Novo Nordisk's patient assistance program: NovoCare
• Eli Lilly's savings program: Lilly Cares Foundation

4. Explore Marketplace or Spouse Coverage

If you have a qualifying life event (and losing a specific benefit may count as one in some states), you might be able to switch to a marketplace plan that includes GLP-1 coverage. Some ACA marketplace plans do cover these medications, though policies vary widely by insurer and state.

Telehealth Providers: A Lower-Cost Alternative Worth Knowing

One of the most practical alternatives for people who lose employer GLP-1 coverage is telehealth. A growing number of licensed telehealth platforms prescribe compounded semaglutide or tirzepatide at a fraction of the brand-name cost.

Compounded medications are copies of FDA-approved drugs mixed by licensed compounding pharmacies. During the FDA shortage period for semaglutide and tirzepatide, these were widely available. The shortage status has changed, which affects legal availability, so it is important to work with a provider who is current on the regulatory landscape.

Even so, many telehealth platforms offer brand-name GLP-1 prescriptions with transparent pricing, and some negotiate directly with pharmacies for lower rates. Comparing GLP-1 providers can help you find a legitimate, licensed option that fits your budget.

What to Look for in a Telehealth GLP-1 Provider

• Licensed physicians or nurse practitioners in your state
• Clear pricing with no hidden fees
• Ongoing clinical support, not just a prescription and no follow-up
• Transparent sourcing of any compounded medications (licensed 503A or 503B pharmacy)
• Easy communication if you experience side effects

Coupons, Discount Cards, and Other Cost-Reduction Tools

Even if you end up paying out of pocket, you are not entirely without options for reducing the cost. Prescription discount programs like GoodRx, NeedyMeds, and manufacturer coupons can meaningfully reduce what you pay at the pharmacy counter.

The savings vary dramatically by medication and pharmacy, so it pays to compare before you fill. For example, GoodRx prices for Ozempic can vary by hundreds of dollars depending on which pharmacy you use in your area.

You can also explore GLP-1 coupons and savings programs that have been vetted for legitimacy. Be cautious of third-party sites offering deeply discounted or unverified medications, particularly those sourced from outside the United States.

The Bigger Picture: A National Coverage Crisis for Obesity Medication

The UVM Health decision is a symptom of a much larger problem. Despite obesity being recognized as a chronic disease by the American Medical Association and major clinical bodies, insurance coverage for obesity medications remains inconsistent, inequitable, and fragile.

Medicare currently does not cover GLP-1 drugs for weight loss only (though this may be changing under evolving federal policy). Medicaid coverage varies by state. And private employer coverage, as UVM Health employees are now experiencing firsthand, can disappear at any time during an open enrollment cycle.

This coverage volatility creates a real clinical problem. GLP-1 medications work best as long-term treatments. Stopping them due to cost leads to weight regain in most patients, which has its own health consequences including increased cardiovascular risk and worsening metabolic markers.

For patients who have experienced meaningful results on these medications, an abrupt coverage cut is not just a financial inconvenience. It is a clinical disruption.

What This Means for You and How to Move Forward

If you are a UVM Health employee facing this coverage cut, or if you work for any employer that is reconsidering GLP-1 benefits, the most important thing you can do right now is plan ahead. Do not wait until your coverage actually ends to start exploring alternatives.

Here is a practical checklist to get started:

• Confirm your last covered fill date with HR or your benefits administrator
• Schedule a conversation with your prescribing doctor about your options and any possible dose adjustments
• Apply for manufacturer assistance programs as soon as possible, since processing can take several weeks
• Compare telehealth providers to understand what compounded or brand-name options are available in Vermont at what cost
• Check GoodRx and other discount tools to see real-time pricing at pharmacies near you
• Review your marketplace options if you think you may qualify for a plan with better GLP-1 coverage

The loss of employer coverage is frustrating, especially when you have seen real results from your medication. But it does not have to mean the end of your treatment. The landscape for accessing GLP-1 medications outside of traditional insurance has grown considerably, and there are legitimate, affordable paths available to many patients.

A Note on Continuing Your Care Safely

Whatever you decide, please do not make changes to your GLP-1 medication without consulting your doctor. This includes stopping, reducing your dose, or switching to a different product. GLP-1 medications affect appetite hormones, blood sugar, and cardiovascular function, and any changes should be guided by a qualified clinician who knows your full health history.

If you are currently managing both obesity and a condition like type 2 diabetes, the stakes are even higher. Losing access to your medication without a plan could have consequences beyond weight regain.

The Bottom Line

UVM Health's decision to cut GLP-1 weight-loss coverage for employees is a reminder of how vulnerable access to these medications can be, even for people who work within the healthcare system itself. The cost burden is real, and the options require some research and effort to navigate.

But options do exist. From manufacturer assistance programs and prescription discount tools to telehealth platforms offering brand-name or compounded alternatives, many patients have found ways to maintain access to their treatment after losing employer coverage.

At GLP-1.com, we track the providers, pricing, and resources that can help you stay on track. If you are newly uninsured for your GLP-1 medication, start by comparing GLP-1 providers to find a licensed telehealth option that fits your budget. You can also browse GLP-1 coupons and savings tools we have vetted for legitimacy and value.

You put in the work to start this treatment. Getting informed about your options is the next step in protecting that progress.